Johnson & Johnson Reports Earnings Tuesday. What to Expect.
Pharmaceuticals firm Johnson & Johnson kicks off earnings season for the sector on Tuesday. Investors want executives to put to rest ongoing talc litigation.
3 Blue Chip Stocks For Your April 2024 Watchlist
Blue Chip stocks to watch in the stock market today.
Rwanda joins other African countries in recalling J&J children's cough syrup
Rwanda's drug regulator has recalled a batch of Johnson & Johnson children's cough syrup as a precautionary measure after its Nigerian counterpart said laboratory tests found high levels of toxicity.
South Africa recalls J&J's cough syrup sold in six African nations after suspected toxicity
South Africa's health regulator said on Saturday it is recalling batches of Johnson & Johnson's children's cough syrup after detection of high levels of diethylene glycol.
J&J (JNJ) to Begin Pharma Q1 Earnings Season: What's in Store?
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
Johnson & Johnson: Doubling Down On This 2024 Dog Of The Dow
Johnson & Johnson: Doubling Down On This 2024 Dog Of The Dow
Johnson & Johnson expected to face dip in first-quarter earnings
Johnson & Johnson (NYSE:JNJ) will report first quarter results next Tuesday, 16 April, hot on the heels of its acquisition of Shockwave Medical. This US$13.1 billion deal saw J&J move further into ...
Rallybio partners with J&J to advance therapies targeting rare fetal disease
Rallybio announced it is collaborating with Johnson & Johnson (NYSE:JNJ) on the development of therapies aimed at reducing the risk of a rare fetal disease called fetal and neonatal alloimmune thro...
Unlocking Q1 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Johnson & Johnson (JNJ), delve into some of its key metrics to gain a deeper insight into the company's potential performanc...
Nigeria recalls J&J children's cough syrup over toxic substance
Nigeria's health regulator is recalling a batch of Johnson & Johnson children's cough syrup after finding an unacceptably high level of a potentially fatal toxic substance, it said on Wednesday.
What's Next For Johnson & Johnson Stock After A 6% Decline In A Month?
Johnson & Johnson (NYSE: JNJ) recently announced its plans to acquire Shockwave Medical for $13 billion. Shockwave will help J&J extend its offerings in the cardiovascular intervention market.
Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?
Johnson & Johnson is buying Shockwave Medical for $13.1 billion. Shockwave is a profitable company that expects to generate more than $900 million in sales this year.
Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Johnson & Johnson (JNJ) Fell More Than Broader Market
In the latest trading session, Johnson & Johnson (JNJ) closed at $151.59, marking a -0.52% move from the previous day.
Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at the InterContinental Bar...
Related Companies